TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant schizophrenia. The Phase 2 ...
Two separate research teams used base editing to make single-nucleotide changes in human embryos this month, targeting genes ...
United Therapeutics is a Buy: strong core growth, a goal of $1B quarterly revenue by 2027, plus catalysts ralinepag & Tyvaso ...
The Indian government has strengthened oversight of cell and gene therapies by bringing the novel modalities into the ...
ILOILO CITY — Justice is within reach for the family of a slain motorist in this city, following the surrender of a dismissed police officer who had been evading an arrest warrant for nearly four ...
The ongoing battle against neglected tropical diseases (NTDs) and pandemic pathogens such as COVID-19 has exposed significant deficiencies in our ...
Objectives Elective non-emergent surgical wait times have increased across countries such as Canada, straining operating room ...